Anticoagulation for Atrial Fibrillation Ablation in Australia

Atrial fibrillation remains the most common sustained arrhythmia managed by Australian cardiologists and electrophysiologists, with prevalence rising sharply in patients over 65 years of age. Catheter ablation has matured into a first-line rhythm control option for many of these individuals, yet periprocedural stroke and bleeding remain the two sentinel complications that shape every decision in the electrophysiology laboratory. The question of whether to continue or interrupt oral anticoagulation around the time of pulmonary vein isolation sits at the centre of modern ablation safety protocols.

Across hospitals in Sydney, Melbourne, Brisbane, Perth, and Adelaide, the conversation has shifted considerably over the past decade. Early practice favoured stopping warfarin, bridging with heparin, and resuming anticoagulation only after haemostasis was secured. Contemporary trials and registry data now favour a strategy that minimises the time a patient spends without an effective antithrombotic agent, aligning with Australian guidance issued through the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand.

The case for an uninterrupted strategy

Uninterrupted anticoagulation means that a patient takes their usual dose of vitamin K antagonist or direct oral anticoagulant on the morning of the procedure and throughout the periprocedural window, with intraprocedural heparin titrated to a target activated clotting time. The conceptual advantage is straightforward: the left atrial appendage and any freshly created ablation lesions are never exposed to a prothrombotic rebound window.

The landmark COMPARE trial randomised patients to warfarin continuation versus interruption with bridging and demonstrated a substantial reduction in periprocedural stroke in the uninterrupted arm, without an excess of major bleeding. Subsequent meta-analyses reinforced that signal, showing roughly a two-thirds relative reduction in silent cerebral events when anticoagulation was maintained throughout. For Australian operators managing high-volume lists at centres such as Royal Melbourne or Westmead, the practical translation has been a move towards protocolised uninterrupted pathways embedded in pre-admission checklists.

One persistent concern has been cardiac tamponade, the most feared acute complication of AF ablation. Large international registries, including data captured through the ANZACS-QI framework, suggest that uninterrupted anticoagulation does not increase the rate of tamponade requiring drainage, provided that heparin is reversed with protamine at the end of the case and that meticulous sheath management is observed. Local audits from Victorian and New South Wales laboratories have produced concordant findings, supporting the safety profile of the uninterrupted approach in real-world Australian practice.

Interrupted warfarin and the limits of bridging

The interrupted approach was historically driven by concerns about bleeding from femoral access sites and the steep INR fluctuations seen when warfarin is held for several days. Bridging with low molecular weight heparin was thought to protect against thromboembolism during this vulnerable window, but the BRIDGE study and related analyses undermined that assumption in atrial fibrillation patients with moderate stroke risk.

For the ablation population specifically, bridging is associated with higher rates of pericardial effusion and access-site haematoma. The pharmacokinetics of enoxaparin overlap with the residual anticoagulant effect of warfarin in a way that creates a narrow therapeutic window around the procedure. In contemporary Australian practice, bridging is largely reserved for patients with mechanical heart valves or recent thromboembolism, populations that make up only a small fraction of AF ablation referrals.

Operators in regional centres, where point-of-care INR turnaround may be slower than in metropolitan quaternary hospitals, have found that maintaining warfarin through the ablation simplifies logistics and removes the need for daily INR checks in the days leading up to the procedure. This has practical appeal for patients travelling long distances from rural New South Wales or the Wheatbelt region of Western Australia to reach the nearest electrophysiology service.

Direct oral anticoagulants and the changing landscape

Direct oral anticoagulants have transformed the field since their inclusion on the Pharmaceutical Benefits Scheme for stroke prevention in non-valvular atrial fibrillation. Their predictable pharmacokinetics, rapid onset, and short half-life make them particularly well suited to periprocedural management around ablation.

The RE-CIRCUIT trial established that uninterrupted dabigatran during ablation was associated with fewer major bleeding events than uninterrupted warfarin, while AXIOM-AF and ELIMINATE-AF extended the safety profile to apixaban and edoxaban. Australian electrophysiologists have largely adopted an uninterrupted DOAC strategy, often with the last dose given the evening before the procedure rather than the morning of, to balance bleeding risk against the need for adequate anticoagulant coverage on the day of ablation.

Practical considerations include timing the last dose relative to general anaesthesia, ensuring reliable reversal agents are available on site, and counselling patients about resuming their usual schedule. Idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors are increasingly stocked in tertiary centres, although andexanet alfa access remains uneven across Australian sites, with availability concentrated in larger metropolitan hospitals. Related explorations of how computational tools are reshaping rhythm care are described in current work on AI in ECG interpretation for arrhythmia screening.

Bleeding and thromboembolic risk stratification

Risk stratification has become more nuanced than a binary decision to interrupt or continue. The CHA₂DS₂-VASc score identifies patients at highest thromboembolic risk, but periprocedural risk is shaped by additional factors such as left atrial size, duration of AF, and the presence of spontaneous echo contrast on transoesophageal echocardiography. Body mass index, sleep apnoea, and atrial anatomy variants all influence both thromboembolic susceptibility and the technical difficulty of the case.

On the bleeding side, HAS-BLED provides a useful framework but does not capture ablation-specific risks. Large-bore femoral access, transseptal puncture, and extensive ablation lesion sets all modulate the probability of complications. Patient-level factors such as age over 75, female sex, renal impairment, and the use of antiplatelet agents for concurrent coronary disease further complicate the picture.

In Australian cohorts, registry analyses have identified a non-trivial incidence of subclinical cerebral emboli detected on post-procedural MRI, even in patients maintained on uninterrupted anticoagulation. Whether these silent events translate into long-term cognitive change remains an area of active investigation. The interplay between autonomic tone and procedural outcomes is also being revisited, and recent reviews on Autonomic Modulation for Vasovagal Syncope: Pacing and Ablation touch on adjacent mechanistic themes relevant to ablation physiology.

Australian practice patterns and guideline alignment

Local registries and audits indicate that the vast majority of Australian ablation procedures are now performed on uninterrupted oral anticoagulation, with DOACs dominating the periprocedural landscape. The CSANZ clinical guidance position statements emphasise that periprocedural anticoagulation decisions should be protocolised at the institutional level and that operators should avoid ad hoc interruption unless a specific clinical indication arises, such as active bleeding or a procedure requiring very high bleeding-risk instrumentation.

Day-of-procedure checklists in many Australian labs include confirmation of the last anticoagulant dose, verification of renal function for DOAC dosing, and documentation of reversal agent availability. Nursing-led pre-admission clinics in cities like Adelaide and Brisbane have taken ownership of much of this workflow, reducing cancellations and improving compliance with perioperative protocols. Telehealth follow-up has also become routine for patients living outside metropolitan catchments, allowing dose reconciliation and bleeding surveillance without the burden of long travel in the days after the procedure.

Looking ahead, ablation energy sources such as pulsed field ablation may further refine bleeding risk by producing more selective myocardial lesions, but periprocedural anticoagulation will remain a cornerstone of safe practice regardless of the modality used. Heat-related dehydration during Australian summers can complicate early post-procedural recovery in patients on continuous anticoagulation, making patient education about hydration and timely dose resumption a practical priority for outpatient teams.

Readers interested in contributing to the evidence base on periprocedural management, autonomic modulation, or AI-driven arrhythmia detection are invited to submit original work to the Journal of Arrhythmia and explore the latest themed collections on the journal platform. Clinicians and trainees can access current articles, special issues, and manuscript submission information directly through the journal homepage.